Market capitalization | GBP1.30b |
Enterprise Value | GBP1.27b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 13.00 |
EV/Sales (TTM) EV/Sales | 0.83 |
P/S ratio (TTM) P/S ratio | 0.85 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 83.27% |
Revenue (TTM) Revenue | GBP1.52b |
As a Free StocksGuide user, you can view scores for all 6,838 stocks worldwide.
7 Analysts have issued a Indivior forecast:
7 Analysts have issued a Indivior forecast:
Mar '25 |
+/-
%
|
||
Revenue | 1,520 1,520 |
83%
83%
|
|
Gross Profit | 1,276 1,276 |
86%
86%
|
|
EBITDA | 412 412 |
94%
94%
|
EBIT (Operating Income) EBIT | 393 393 |
107%
107%
|
Net Profit | -41 -41 |
1,199%
1,199%
|
In millions GBP.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom.
Head office | United Kingdom |
CEO | Joseph Ciaffoni |
Employees | 1,041 |
Founded | 2014 |
Website | www.indivior.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.